[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP2675471A4 - Compositions liées à la sérumalbumine humaine et procédés d'utilisation - Google Patents

Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Info

Publication number
EP2675471A4
EP2675471A4 EP11858565.2A EP11858565A EP2675471A4 EP 2675471 A4 EP2675471 A4 EP 2675471A4 EP 11858565 A EP11858565 A EP 11858565A EP 2675471 A4 EP2675471 A4 EP 2675471A4
Authority
EP
European Patent Office
Prior art keywords
hsa
methods
related compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11858565.2A
Other languages
German (de)
English (en)
Other versions
EP2675471A1 (fr
Inventor
Changshou Gao
Chaity Chaudhury
Xiaotao Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/024855 external-priority patent/WO2011103076A1/fr
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2675471A1 publication Critical patent/EP2675471A1/fr
Publication of EP2675471A4 publication Critical patent/EP2675471A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11858565.2A 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation Withdrawn EP2675471A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/024855 WO2011103076A1 (fr) 2010-02-16 2011-02-15 Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
PCT/US2011/047040 WO2012112188A1 (fr) 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2675471A1 EP2675471A1 (fr) 2013-12-25
EP2675471A4 true EP2675471A4 (fr) 2015-01-28

Family

ID=46675795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11858565.2A Withdrawn EP2675471A4 (fr) 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Country Status (7)

Country Link
EP (1) EP2675471A4 (fr)
JP (1) JP2014510518A (fr)
KR (1) KR20140012094A (fr)
CN (1) CN103379915A (fr)
AU (1) AU2011359378A1 (fr)
CA (1) CA2826683A1 (fr)
WO (1) WO2012112188A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2396347T3 (en) 2009-02-11 2017-07-24 Albumedix As ALBUMIN VARIANTS AND CONJUGATES
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
EP2536756B1 (fr) 2010-02-16 2018-04-25 MedImmune, LLC Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
MX343580B (es) 2011-06-13 2016-11-10 Csl Ltd Anticuerpos contra el g-csfr y sus usos.
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
US20140128326A1 (en) * 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
ES2648591T3 (es) 2013-02-16 2018-01-04 Albumedix A/S Modelo animal farmacocinético
ES2660912T3 (es) * 2013-03-15 2018-03-26 Affibody Ab Nuevos polipéptidos
WO2014198834A1 (fr) * 2013-06-12 2014-12-18 Pharis Biotec Gmbh Peptides ayant des activités d'antagoniste contre cxcr4 naturel
US20160222087A1 (en) * 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
EP3063171B1 (fr) * 2013-11-01 2019-07-24 University Of Oslo Variants d'albumine et utilisations de ceux-ci
EP3842451A1 (fr) 2015-03-12 2021-06-30 MedImmune, LLC Procédé de purification de protéines de fusion d'albumine
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
CN108290941A (zh) * 2015-09-23 2018-07-17 百时美施贵宝公司 快解离速率的血清白蛋白结合性纤连蛋白iii型结构域
CN108431204A (zh) 2015-12-22 2018-08-21 阿尔布梅迪克斯医疗有限公司 改良的表达蛋白质的菌株
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
KR102638505B1 (ko) 2017-06-20 2024-02-20 알부메딕스 리미티드 개선된 단백질 발현 스트레인
PL3717011T3 (pl) 2017-11-29 2023-03-27 Csl Limited Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu
BR112020022405A2 (pt) 2018-05-16 2021-04-13 Csl Limited Variantes de receptor de complemento solúvel tipo 1 e usos dos mesmos
JP2022509372A (ja) 2018-10-29 2022-01-20 バイオジェン・エムエイ・インコーポレイテッド 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
US20230220048A1 (en) 2019-09-06 2023-07-13 Novartis Ag Therapeutic fusion proteins
WO2021111143A1 (fr) 2019-12-04 2021-06-10 Albumedix Limited Procédés et compositions produites par ceux-ci
CN114478800B (zh) * 2021-02-05 2022-10-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
WO2024089258A1 (fr) 2022-10-28 2024-05-02 Aarhus Universitet Albumine conjuguée à des oligodésoxynucléotides cpg en tant que super composés adjuvants de la réponse immunitaire
EP4442251A1 (fr) 2023-04-05 2024-10-09 Albumedix Ltd Formulations et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (fr) * 2010-02-16 2011-08-25 Medlmmune, Llc Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
MX2010011145A (es) * 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
US20120076728A1 (en) * 2009-04-08 2012-03-29 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (fr) * 2010-02-16 2011-08-25 Medlmmune, Llc Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012112188A1 *

Also Published As

Publication number Publication date
CA2826683A1 (fr) 2012-08-23
EP2675471A1 (fr) 2013-12-25
CN103379915A (zh) 2013-10-30
AU2011359378A1 (en) 2013-10-03
KR20140012094A (ko) 2014-01-29
WO2012112188A1 (fr) 2012-08-23
JP2014510518A (ja) 2014-05-01

Similar Documents

Publication Publication Date Title
EP2675471A4 (fr) Compositions liées à la sérumalbumine humaine et procédés d'utilisation
EP2536756A4 (fr) Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2584897A4 (fr) Compositions contenant du resvératrol et procédés d'utilisation
HK1193837A1 (zh) 聚脲組合物及其使用方法
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
HK1202244A1 (en) Prebiotic formulations and methods of use
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
EP2836218A4 (fr) Compositions prébiotiques et leurs procédés d'utilisation
EP2836224A4 (fr) Compositions de microbiota et leurs procédés associés
HK1203049A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2772483A4 (fr) Compose 4-aminocarbazole et son utilisation
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
SG11201501499SA (en) Multi-functional compositions and methods of use
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
EP2596112A4 (fr) Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
EP2667889A4 (fr) Compositions de wnt et procédés d'utilisation de celles-ci
EP2704688A4 (fr) Compositions de cochléate et leurs procédés de fabrication et d'utilisation
IL227924B (en) Preparations and methods of use for determining a4he
EP2753337A4 (fr) Compositions comprenant des bêta-glucanes et leurs procédés d'utilisation
EP2906041A4 (fr) Compositions et procédés d'utilisation d'un composé de lutte contre l'inappétence
EP2755668A4 (fr) Compositions dérivées de hyr1 et méthodes de traitement les utilisant
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
ZA201308892B (en) Compositions and methods
EP2670245A4 (fr) Alpha-cétohétérocycles et leurs procédés de fabrication et d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192466

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20150108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/765 20060101ALI20141222BHEP

Ipc: A61K 47/48 20060101ALI20141222BHEP

Ipc: A61K 38/38 20060101AFI20141222BHEP

17Q First examination report despatched

Effective date: 20150907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160318

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192466

Country of ref document: HK